# Altimmune to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-90ad12d9
Ticker: ALT
Company: Altimmune
Source: Altimmune
Published: 2026-05-27 12:30 EST
## Summary

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide...

## Article Body
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

2026 Jefferies Global Healthcare Conference Thursday, June 4, 2026 Fireside chat at 12:50 p.m. ET New York, NY

Goldman Sachs 47 th Annual Global Healthcare Conference Wednesday, June 10, 2026 Fireside chat at 8:00 a.m. ET Miami Beach, FL

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .

Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X

Investor Contact: Luis Sanay, CFA Vice President, Investor Relations ir@altimmune.com

Media Contact: Real Chemistry altimmune@realchemistry.com
## Recent Company News
- 2026-07-28 11:00 EST — [Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder](https://biopharmsignal.com/news/ALT/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvi-1fc61fa7) — Source: Altimmune
- 2026-05-28 15:00 EST — [Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026](https://biopharmsignal.com/news/ALT/pemvidutide-demonstrates-significant-metabolic-improvements-in-patients-with-mas-a943260b) — Source: Altimmune
- 2026-05-27 12:30 EST — [Altimmune to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-90ad12d9) — Source: Altimmune
- 2026-05-27 12:00 EST — [New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026](https://biopharmsignal.com/news/ALT/new-impact-phase-2b-data-highlight-concurrent-improvements-across-multiple-non-i-c3ed7d9e) — Source: Altimmune
- 2026-05-13 11:30 EST — [Altimmune Announces First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALT/altimmune-announces-first-quarter-2026-financial-results-and-business-update-8b5f5558) — Source: Altimmune
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)